Clinical Report: Revisiting Lifitegrast in DED

Overview

A review of lifitegrast 5% ophthalmic solution summarizes its LFA-1–blocking mechanism and evidence from clinical trials, safety analyses, and real-world studies in dry eye disease (DED). Across the OPUS trials, effects differed between signs and symptoms; reported safety findings were broadly consistent, with instillation-site events and dysgeusia among the common adverse events.

Background

DED is a heterogeneous, multifactorial condition in which inflammation is recognized as an important, but not universal, driver. Lifitegrast is an LFA-1 antagonist indicated for the treatment of DED signs and symptoms; it blocks LFA-1 interaction with ICAM-1 and thereby interferes with T-cell activation, migration, and inflammatory cytokine release. The American Academy of Ophthalmology’s 2024 Preferred Practice Pattern lists topical LFA-1 antagonists among prescription options within staged DED management. The review describes lifitegrast as one option in a personalized treatment landscape and notes that its conclusions should be interpreted in light of disclosed industry relationships and funded medical writing assistance.

Data Highlights

Key Findings

• Lifitegrast blocks the LFA-1/ICAM-1 interaction, affecting several points in the ocular surface inflammatory cascade; the review contrasts this cell-surface action with cyclosporine’s intracellular immunomodulatory mechanism.
• OPUS-1 showed a significant improvement in inferior corneal staining versus vehicle, while OPUS-2 did not meet its corneal staining coprimary endpoint.
• Eye dryness improved significantly in OPUS-2 and OPUS-3; in both trials, the review reports an effect apparent by day 14.
• A pooled post hoc analysis of OPUS-2 and OPUS-3 found greater odds of clinically meaningful improvement in both corneal staining and eye dryness with lifitegrast.
• Across five randomized trials involving 2,464 patients, common ocular adverse events included instillation-site irritation, reaction, and pain; dysgeusia was reported in 14.5% of lifitegrast-treated patients and 0.3% of vehicle-treated patients. Overall discontinuation because of adverse events was described as relatively low.
• Real-world reports generally described improvements in symptoms, clinical signs, and quality of life, while treatment persistence remained a challenge. The review also describes emerging use for preoperative ocular surface optimization before cataract surgery, associated with improved keratometry reproducibility and refractive accuracy.

Clinical Implications

The AAO’s 2024 Preferred Practice Pattern includes topical LFA-1 antagonists among prescription options for staged DED management, with treatment selection based on disease severity and clinician judgment. The review reports that sign and symptom outcomes may diverge and that dysgeusia and instillation-site events are relevant safety findings to discuss; it also identifies treatment persistence as a challenge.

Conclusion

The review positions lifitegrast as an anti-inflammatory option for DED supported by clinical-trial and real-world evidence, while noting variability in sign and symptom outcomes and the importance of considering safety and treatment persistence. Its conclusions should be read alongside the reported funding and author disclosures.

Related Resources & Content

1. American Academy of Ophthalmology, Ophthalmology, 2024 -- Dry Eye Syndrome Preferred Practice Pattern®
2. Holland et al., PubMed, 2013 -- Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study
3. Ophthalmology Management, 2017 -- Xiidra’s 1st 8 months: So far, so good
4. ophthalmology management — Xiidra’s 1st 8 months: So far, so good
5. Ophthalmology Management — Adding Interventional DED Treatment to Your Practice
6. Ophthalmology Management — QUICK HITS
7. Dry Eye Syndrome Preferred Practice Pattern® - Ophthalmology
8. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study
9. Xiidra’s 1st 8 months: So far, so good